Travere Therapeutics (NASDAQ: TVTX) — Perfil da empresa, notícias e dados financeiros
Travere Therapeutics is a biopharmaceutical company dedicated to developing therapies for rare diseases in nephrology and hepatology.
Travere Therapeutics
Travere Therapeutics (NASDAQ:TVTX) is a biopharmaceutical company dedicated to identifying, developing, and delivering life-changing therapies for patients living with rare diseases. Specializing in nephrology, hepatology, and metabolic disorders, Travere Therapeutics focuses on advancing its diverse pipeline of innovative treatments. With projects ranging from pre-clinical discovery phases to late-stage trials, the company aims to address the unmet medical needs within these complex conditions. Among its objectives, Travere Therapeutics strives to enhance patient care and bring novel solutions to the market, leveraging cutting-edge science and strategic partnerships. Currently, the company’s shares are traded exclusively on the NASDAQ stock market, showcasing its commitment to growth and value for shareholders.
Resumo
Operações
Produtos e/ou serviços de Travere Therapeutics
- Sparsentan for focal segmental glomerulosclerosis and IgA nephropathy, representing a potential first-in-class therapy.
- Fosmetpantotenate (RE-024), a novel treatment for pantothenate kinase-associated neurodegeneration, offering hope to a rare disease community.
- Chenodal (chenodeoxycholic acid) for cerebrotendinous xanthomatosis, aiming to reduce cholesterol and bile acid synthesis.
- Thiola (tiopronin) for cystinuria, helping patients manage high cystine levels in urine and prevent kidney stones.
- Orphan drug development program, focusing on therapies for rare diseases that currently have few or no treatment options.
- Partnership initiatives aimed at enhancing access to orphan drugs and supporting the rare disease community through collaboration.
equipe executiva do Travere Therapeutics
- Eric M. DubePresident, CEO & Director
- Christopher ClineChief Financial Officer
- William E. RoteChief Research Officer
- Peter HeermaChief Commercial Officer
- Jula InrigExecutive VP, Head of Research & Development and Chief Medical Officer
- Sandra CalvinSVP & Chief Accounting Officer
- Nivi NehraVice President of Corporate Communications & Investor Relations
- Elizabeth E. ReedChief Legal Officer, General Counsel & Secretary
- Angela GiannantonioChief People Officer
- Casey LoganChief Business Officer
Últimas notícias sobre a Travere Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Travere Therapeutics, em USD.
- Cap. de mercado
- 4,7 bi
- Receita (TTM)
- 591,3 mi
- P/L
- —
- LPA (diluído, TTM)
- -0.7
- Dividend yield
- —
- Margem de lucro
- -7.3%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 490,7 mi | -62,8 mi | -25,5 mi | |
| 233,2 mi | -323,8 mi | -321,5 mi | |
| 145,2 mi | -388,1 mi | -111,4 mi | |
| 109,5 mi | -319,8 mi | -278,5 mi |